PriceTargets.com logo

Vaxart - VXRT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 297.04%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.76 As of 04/19/2024 01:00 AM ET
▼ -0.09 (-10.64%)

This chart shows the closing price for VXRT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaxart Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VXRT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VXRT

Analyst Price Target is $3.00
▲ +297.04% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaxart in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a 297.04% upside from the last price of $0.76.

This chart shows the closing price for VXRT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Vaxart. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2024B. RileyUpgradeNeutral ➝ Buy$2.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$4.00Low
8/7/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$6.00 ➝ $4.00Low
12/19/2022B. RileyLower TargetNeutral$6.00 ➝ $1.50Low
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
9/2/2022Cantor FitzgeraldLower TargetOverweight$11.00 ➝ $8.00Low
5/19/2022B. RileyLower TargetNeutral$7.00 ➝ $6.00High
11/12/2021Piper SandlerReiterated RatingOverweight$18.00High
11/2/2021Cantor FitzgeraldInitiated CoverageOverweight$15.00High
6/29/2021B. RileyDowngradeBuy ➝ Neutral$13.00 ➝ $9.00Medium
6/24/2021Jefferies Financial GroupInitiated CoverageBuy$13.00High
6/11/2021Piper SandlerInitiated CoverageOverweight$18.00High
3/4/2021B. RileyReiterated RatingBuy$16.00 ➝ $13.00High
12/3/2020B. RileyReiterated RatingBuy$22.00High
11/18/2020B. RileyLower TargetBuy$22.00 ➝ $16.00Low
8/12/2020HC WainwrightBoost TargetBuy$7.00 ➝ $17.00High
8/7/2020B. RileyReiterated RatingBuy$22.00Low
7/12/2020B. RileyInitiated CoverageBuy$22.00High
5/13/2020HC WainwrightReiterated RatingBuy$7.00High
4/30/2020HC WainwrightReiterated RatingBuy$3.00 ➝ $7.00High
4/23/2020HC WainwrightReiterated RatingBuy$3.00Medium
3/19/2020HC WainwrightReiterated RatingBuy$3.00High
11/18/2019HC WainwrightReiterated RatingBuy$2.00High
8/21/2019HC WainwrightSet TargetBuy$2.00High
8/15/2019Brookline Capital ManagementInitiated CoverageBuy$6.00Low
6/27/2019HC WainwrightInitiated CoverageBuy$2.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vaxart logo
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.76
Low: $0.75
High: $0.86

50 Day Range

MA: $1.17
Low: $0.84
High: $1.41

52 Week Range

Now: $0.76
Low: $0.53
High: $1.59

Volume

1,905,572 shs

Average Volume

1,987,615 shs

Market Capitalization

$131.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaxart?

The following equities research analysts have issued reports on Vaxart in the last year: B. Riley, and Cantor Fitzgerald.
View the latest analyst ratings for VXRT.

What is the current price target for Vaxart?

2 Wall Street analysts have set twelve-month price targets for Vaxart in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 297.0%. Cantor Fitzgerald has the highest price target set, predicting VXRT will reach $4.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $2.00 for Vaxart in the next year.
View the latest price targets for VXRT.

What is the current consensus analyst rating for Vaxart?

Vaxart currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VXRT will outperform the market and that investors should add to their positions of Vaxart.
View the latest ratings for VXRT.

What other companies compete with Vaxart?

Other companies that are similar to Vaxart include INmune Bio, 10X Capital Venture Acquisition Corp. III, LENZ Therapeutics, Molecular Partners and Cellectis. Learn More about companies similar to Vaxart.

How do I contact Vaxart's investor relations team?

Vaxart's physical mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company's listed phone number is (650) 550-3500 and its investor relations email address is [email protected]. The official website for Vaxart is www.vaxart.com. Learn More about contacing Vaxart investor relations.